We found that expressions of miR-7, FAK, ERK and MAPK are associated with LNM and TNM stages in NSCLC patients, posing a potential role of miR-7 and its downstream pathway as non-invasive biomarkers for assessing NSCLC clinical outcome. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.